CARLSBAD, Calif., May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of treatment for both monthly or every two-month dosing. Patients who switched to donidalorsen from prior prophylactic treatment also sh ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

In a shortened week of trading following the Memorial Day weekend, investors may want to take notice of several medical stocks that were added to the Zacks Rank #1 (Strong Buy) list today. Standing out in terms of valuation with earnings estimates on the rise as well, here are three of these highly ranked medical stocks to consider. Haemonetics (HAE) More intriguing is that Lantheus' P/E valuation of 11X looks cheap especially considering FY24 earnings estimates have spiked 8% over the last 30 days while FY ...

Haemonetics' shares gained 21% over the last three month compared with the S&P 500's advance of 1.1%. The company possesses a Momentum Score of B. Lightspeed Commerce Inc. (LSPD) : This cloud services provider has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.7% over the last 60 days. Lightspeed Commerce's shares gained 7.9% over the last three months compared with the S&P 500's advance of 1.1%. The company possesses a Momentum Score of A. Haemonetics ...

In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Haemonetics (HAE) is on the list of such stocks currently recommended b ...

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with po ...

Haemonetics (HAE) closed the last trading session at $88.64, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.20 indicates a 26.6% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $12.15. While the lowest estimate of $94 indicates a 6.1% increase from the current price level, the most optimistic analyst expect ...

Haemonetics (HAE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Indiv ...

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amo ...

Haemonetics (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company's hospital portfolio is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from economic uncertainties and adverse foreign exchange effects are concerns for Haemonetics' operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 11.7% against the 1.3% fall of the indus ...